Strain vessel hypothesis: A viewpoint for linkage of albuminuria and cerebro-cardiovascular risk

Hypertension Research

Volumn 32, Issue 2, 2009, Pages 115-121

  Ito, Sadayoshi ^a   Nagasawa, Tasuku ^a   Abe, Michiaki ^a   Mori, Takefumi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD FLOW VELOCITY; CAPILLARY PRESSURE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY BLOOD FLOW; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; HUMAN; HYPERTENSION; HYPERTENSION RETINOPATHY; KIDNEY BLOOD FLOW; KIDNEY INJURY; KIDNEY MEDULLA; MICROALBUMINURIA; NATRIURESIS; NONHUMAN; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; RETINA BLOOD FLOW; REVIEW; SODIUM BALANCE; SODIUM EXCRETION; VASOCONSTRICTION;

ALBUMINURIA; ANIMALS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; KIDNEY; NEPHRONS; RISK ASSESSMENT; SODIUM, DIETARY;

EID: 67650372806     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2008.27     Document Type: Review

References (97)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
2. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29: 595-600.
3. Eijkelkamp WEI, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
4. Forman JP, Brenner BM. 'Hypertension' and 'microalbuminuria': The bell tolls for thee. Kidney Int 2006; 69; 22-28.
5. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw 0, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
6. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, Wareham NJ. Microalbuminuria and stroke in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. J Intern Med 2004; 255: 247-256.
7. Ravera M, Ratto E, Vettoretti S, Viazzi F, Leoncini G, Parodi D, Tomolillo C, Del Sette M, Maviglio N, Deferrari G, Pontremoli R. Microalbuminuria and suloclinical cerebrovascular damage in essential hypertension. J Nephrol 2002; 15: 519-524.
8. Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S, Kawanami T, Tajima K, Daimon M, Kato T. Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. J Neurol Sci 2007; 255: 27-34.
9. Cubeddu LX, Hoffmann IS, Aponte LM, Nuñez-Bogesits R, Medina-Suniaga H, Roa M, Garcia RS. Role of salt sensitivity, blood pressure, and hyperinsulinemia in determining high upper normal levels of urinary albumin excretion in a healthy adult population. Am J hypertens 2003; 16: 343-349.
10. Klausen KP, Scharling H, Jensen JS. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med 2006; 260: 231-237.
11. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
12. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310 356-360.
13. Fliser D, Buchholz K, Haller H. EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators: antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107.
14. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006; 47: 699-705.
15. Grimm Jr RH, Svendsen KH, Kasiske B, Keane WIF, Wahi MM. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int 1997; 63: S10-S14.
16. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Hallé JP, Hoogwerf B, Joyce C, Rashkow A, Young J, Zinman B, Yusuf S. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000; 23: B35-B39.
17. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, De Zeeuw D, De Jong PE, Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-526.
18. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephrepathy. Circulation 2004; 110: 921-927.
19. Assellbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816.
20. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force an the Management of Arterial Hypertension. J hypertens 2007; 25: 1751-1762.
21. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: A role for the glomerular endothelium? Diabetologia 2008; 51: 714-725.
22. Nosadini R, Velussi M, Brocco E, Brocco E, Abaterusso C, Piarulli F, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, Tonolo G. Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms. Diabetes 2005; 54: 228-233.
23. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17: 2100-2105.
24. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-323.
25. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potenbal mechanisms. J Am Soc Nephrol 2006; 17: 2106-2111.
26. Malik AR, Sultan S, Turner ST, Kullo IJ. Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults. J Hum Hypertens 2007; 21: 231-238.
27. Kerjaschki D. Dysfunctions of cell biological mechanisms of visceral epithelial cell (podocytes) in glomerular diseases. Kidney Int 1994; 45: 300-313.
28. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
29. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999; 34:973-995.
30. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: A role for the glomerular endothelium? Diabetologia 2008; 51: 714-725.
31. Iversen BM, Amann K, Kvam FI, Wang X, Ofstad J. Increased glomerular capillary pressure and size mediate glomerulosclerosis in SHR juxtamedullary cortex. Am J Physiol 1998; 274: F365-F373.
32. Johnson RJ, Gordon KL, Giachelli C, Kurth T, Skelton MM, Cowley Jr AW. Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. J Hypertens 2000; 18: 1497-1505.
33. Eng E, Veniant M, Floege J, Ingerle J, Alpers CE, Menard J, Clozel JP, Johnson RJ. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens 1994; 7: 177-185.
34. Mori T, Cowley Jr AW. Role of pressure in angiotensin II-induced renal injury: Chronic servo-control of renal perfusion pressure in rats. Hypertension 2004; 43: 752-759.
35. Ericson AC, Sjöquist M, Ulfendahl HR. Heterogeneity in regulation of glomerular function. Acta Physiol Scand 1982; 114: 203-209.
36. Heyeraas KJ, Aukland K. Interlobular arterial resistance: Influence of renal arterial pressure and angiotensin II. Kidney Int 1987; 31 1291-1298.
37. Takenaka T, Suzuki H, Okada H, Hayashi K, Ozawa Y, Saruta T. Biophysical signals underlying myogenic responses in rat interlobular artery. Hypertension 1998; 32: 1060-1065.
38. Inscho EW, Cook AK, Murzynowski JB, Imig JD. Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. J Hypertens 2004; 22: 811-818.
39. Steinhausen M, Endlich K, Weigman DL. Glomerular blood flow. Kidney Int 1990; 38: 739.
40. Navar LG. Renal autoregulation: Perspective from whole kidney and single nephron studies. Am J Physiol 1977; 233: 366.
41. Vallon V, Schnermann J. Tubuloglomerular feedback. Methods Mol Med 2003; 86: 429-441.
42. Thomson SC, Blantz RC. Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis. J Am Soc Nephrol 2008; 19: 2272-2275.
43. Schnermann J, Briggs JP. Tubuloglomerular feedback: Mechanistic insights from gene-manipulated mice. Kidney Int 2008; 74: 418-426.
44. Schnermann J, Bridge JP, Weber PC. Tubuloglomerular feedback, prostaglandins, and angiotensin in the autoregulation of glomerular filtration rate. Kidney Int 1984; 25: 53-64.
45. Cupples WA. Interactions contributing to kidney blood flow autoregulation. Curr Opin Nephrol Hypertens 2007; 16: 39-45.
46. Roald AB, Ofstad J, Iversen BM. Attenuated buffering of renal perfusion pressure variation in juxtamedullary cortex in SHR. Am J Physiol Renal Physiol 2002; 282: 506-511.
47. Bank N, Alterman L, Aynedjian HS. Selective deep nephron hyperfiltration in uninephrectomized spontaneously hypertensive rats. Kidney Int 1983; 24: 185-191.
48. Iversen BM, Amann K, Kvam FI, Wang X, Ofstad J. Glomerular capillary pressure and size mediate glomerulosclerosis in SHR juxtamedullary cortex. Am J Physiol 1998; 274: 365-373.
49. Takenaka T, Forster H, De Micheli A, Epstein M. Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats. Circ Res 1992; 71: 471-480.
50. Hayashi K, Epstein M, Saruta T. Altered myogenic responsiveness of the renal microvasculature in experimental hypertension. J Hypertens 1996; 14: 1387-1401.
51. Carmines PK, Morrison TK, Navar LG. Angiotensin II effects on microvascular diameters of in vitro blood-perfused juxtamedullary nephrons. Am J Physiol 1986; 251: F610-F618.
52. Ichihara A, Imig JD, Inscho EW, Navar LG. Nitric oxide-angiotensin II influences on renal microcirculation in angiotensin II-induced hypertension. Hypertension 1998; 31: 1255-1260.
53. Mori T, Polichnowski A, Glocka P, Kaldunski M, Ohsaki Y, Liang M, Cowley Jr AW. High perfusion pressure accelerates renal injury in salt-sensitive hypertension. J Am Soc Nephrol 2008; 19: 1472-1482.
54. Ito S, Amin J, Ren Y, Arima S, Abe K, Carretero OA. Heterogeneity of angiotensin action in renal circulation. Kidney Int 1997; 63 S128-S131.
55. Bankir L, Kaissling B, de Rouffignac C, Kriz W. The vascular organization of the kidney of Psammomys obesus. Anat Embryol (Berl) 1979; 155: 149-160.
56. Cowley Jr AW, Mori T, Mattson D, Zou AP. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1355-R1369.
57. Ostensen J, Stokke ES. Energy requirement of sodium reabsorption in the thick ascending limb of Henle's loop in the dog kidney: Effects of bumetanide and ouabain. Acta Physiol Scand 1996; 157: 275-281.
58. Blantz RC, Weir M. Are the oxygen costs of kidney function highly regulated? Curr Opin Nephrol Hypertens 2004; 13: 67-71.
59. Kiil F, Sejersted OM. Analysis of energy metabolism and mechanism of loop diuretics in the thick ascending limb of Henle's loop in dog kidneys. Acta Physiol Scand 2003; 178: 73-82.
60. Ostensen J, Stokke ES, Hartmann A, Wensell K, Kiil F. Low oxygen cost of carbonic anhydrase-dependent sodium reabsorption in the dog kidney. Acta Physiol Scand 1989; 137: 189-198.
61. Thurau K. Renal Na reabsorption and O2 uptake in dogs during hypoxia and hydrochlorothiazide infusion. Proc Soc Exp Biol Med 1961; 106 714-717.
62. Goldfarb M, Abassi Z, Rosen S, Shina A, Brezis M, Heyman SN. Compensated heart failure predisposes to outer medullary tubular injury: Studies in rats. Kidney Int 2001; 60: 607-613.
63. Mori T, Cowley AW. Angiotensin II-NAD(P)H oxidase-stimulated superoxide modifies tubulovascular nitric oxide cross-talk in renal outer medulla. Hypertension 2003; 42: 588-593.
64. Mori T, O'Connor PM, Abe M, Cowley Jr AW. Enhanced superoxide production in renal outer medulla of Dahl salt-sensitive rats reduces nitric oxide tubular-vascular cross-talk. Hypertension 2007; 49: 1336-1341.
65. Abe M, O'Connor P, Kaldunski M, Liang M, Roman RJ, Cowley Jr AW. Effect of sodium delivery on superoxide and nitric oxide in the medullary thick ascending limb. Am J Physiol Renal Physiol 2006; 291: 350-357.
66. Mori T, Cowley Jr AW. Renal oxidative stress in medullary thick ascending limbs produced by elevated NaCl and glucose. Hypertension 2004; 43: 341-346.
67. Mori T, Cowley Jr AW, Ito S. Molecular mechanisms and therapeutic strategies of chronic renal injury: Physiological role of angiotensin II-induced oxidative stress in renal medulla. J Pharmacol Sci 2006; 100: 2-8.
68. Dickhout A Mori T, Cowley Jr AW. Tubulovascular nitric oxide crosstalk: buffering of angiotensin II-induced medullary vasoconstriction. Circ Res 2002; 91: 487-493.
69. Azar S, Tobian L, Johnson MA. Glomerular, efferent arteriolar, peritubular capillary, and tubular pressures in hypertension. Am J Physiol 1974; 227: 1045-1050.
70. Greenberg SM. Small vessel, big problem. N Engl J Med 2006; 354 1451-1457.
71. Mohr JP. Progress in cerebrovascular disease. Lacunes. Stroke 1982; 13: 3-10.
72. Auer RN, Sutherland GR. Primary intracerebral hemorrhage: pathophysiology. Can J Neurol Sci 2005; 32: S3-S12.
73. Dubas F. Small vessel pathology and cerebral hemorrhage. J Neuroradiol 2003; 30: 298-302.
74. Hashimoto J, Aikawa T, Imai Y. Large artery stiffening as a link between cerebral lacunar infarction and renal albuminuria. Am J hypertens 2008; 21: 1304-1309.
75. O'Rourke MF, Safar ME. Between aortic stiffening and microvascular disease in brain and kidney: Cause and logic of therapy. Hypertension 2005; 46: 200-204.
76. Struijker Boudier HA, Colnuet GM, Baumann M, Safar ME. Heart, macrocirculation and microcirculation in hypertension: A unifying hypothesis. J hypertens Suppl 2003; 21: S19-S23.
77. Camici PG, Crea F. Microvascular dysfunction. N Engl J Med 2007; 356: 830-840.
78. Porter WT. The influence of the heart-beat on the flow through the walls of the heart. Am J Physiol 1898; 1: 145-163.
79. Gregg DE. Coronary Circulation in Health and Disease. Lea & Febiger: Philadelphia, 1950.
80. Cornelissen AJ, Dankelman J, VanBavel E, Stassen HG, Spaan JA. Myogenic reactivity and resistance distribution in the coronary arterial tree: A model study. Am J Physiol Heart Circ Physiol 2000; 278: H1490-H1499.
81. Huang A, Sun D, Yan C, Falck JR, Kaley G. Contribution of 20-HETE to augmented myogenic constriction in coronary arteries of endothelial NO synthase knockout mice. Hypertension 2005; 46: 607-613.
82. Wong TY, Mitchell P. The eye in hypertension. Lancet 2007; 369 425-435.
83. Weinberger J. Clinical applications of noninvasive carotid artery testing. J Am Coll Cardiol 1985; 5: 137-148.
84. Grosso A, Veglio F, Porta M, Grignolo FM, Wong TY. Hypertensive retinopathy revisited: Some answers, more questions. Br J Ophthalmol 2005; 89: 1646-1654.
85. Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004; 351: 2310-2317.
86. Shigematsu Y, Hamada M, Ohtsuka T, Hashida H, Ikeda S, Kuwahara T, Hara Y, Kodama K, Hiwada K. Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension. Am J Hypertens 1998; 11: 1171-1177.
87. Cuspidi C, Meani S, Salerno M, Fusi V, Severgnini B, Valerio C, Catini E, Esposito A, Magrini F, Zanchetti A. Microvascular changes and target organ damage in untreated essential hypertensives. J hypertens, 2004; 22: 2095-2102.
88. Nesoviæ M, Stojanovim M, Nesoviæ MM, Cirim J, Zarkoviæ M. Microalbuminuria is associated with salt sensitivity in hypertensive patients. J Hum Hypertens 1996; 10: 573-576.
89. Campese VM. Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension 1994; 23: 531-550.
90. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001; 37: 429-432.
91. Guyton AC, Coleman TG, Cowley Jr AV, Scheel KW, Manning Jr RD, Norman Jr RA. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52: 584-594.
92. Cowley Jr AW. Long-term control of arterial blood pressure. Physiol Rev 1992; 72:
93. Cowley Jr AW. Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol 1997; 273: R1-R15.
94. Young JH. Evolution of blood pressure regulation in humans. Curr hypertens Rep 2007; 9: 13-18.
95. Kurokawa K. Kidney, salt, and hypertension: How and why. Kidney Int Supol 1996; 55: S46-S51.
96. Tobian L. Protecting arteries against hypertensive injury. Clin Exp Hypertens, 1992; 14: 35-43.
97. Lee PY, Yun AJ, Bazar KA. Acute coronary syndromes and heart failure may reflect maladaptations of trauma physiology that was shaped during pre-modern evolution. Med Hypotheses 2004; 62: 861-867.